The stubborn residual is judgment — choosing which problems matter. Anthropic names it directly that the missing ingredient ...
Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...
2d
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...
In 2015, AI in drug discovery was still a theoretical pursuit – exciting, but unproven. A few early start-ups were applying deep learning to virtual screening and molecular modelling, but the industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results